Toxoplasma gondii is a protozoan of the Apicomplexa phylum with widespread prevalence in animal and human populations. It has been estimated that about one-third of the world's population is infected with this parasite.
Toxoplasma gondii was first identified in 1908 by Nicole and Manceaux. The parasite is found in almost all continents, including Europe, North and South America, Asia, Africa, the Arctic, and Australia, except the South Pole (
1,
2). Studies have shown that about 30% - 40% of Iranian people are infected with this parasite. The life cycle of
T. gondii requires definite and intermediate hosts (
3). The definite host of this parasite is cats, while the intermediate host is all warm-blooded animals, including domestic animals and humans (
4). Symptoms have a range of asymptomatic, mild, severe, and even fatal. The disease is significant in humans and some animal species, such as goats and sheep, due to congenital infections and can harm the developing fetus or cause miscarriage. Humans become infected with the parasite by eating water or food contaminated with oocysts and eating uncooked meat (
5,
6). Most people with a competent immune system are asymptomatic after infection, and the only sign of infection is a positive serological test, while in individuals with a defective immune system, the initial infection or reactivation of a previous infection can be severe and fatal (
7).
A pregnant mother can transmit the infection to the fetus throughout pregnancy, and the older the gestational age, the greater the chance of transmission but the lower the chance of complications in the fetus (
8,
9). Given that 90% of patients are asymptomatic and, determining the prevalence and serological measurement can be an effective step in diagnosing cases infected with
T. gondii (
10,
11). Mainly, to prevent the effects of disease before pregnancy, giving counseling before marriage about routine laboratory tests can be helpful for reproductive-age women. Whether they are susceptible to acute or chronic infection, therapeutic measures can be linked to the treatment so that non-immune individuals can benefit from special healthcare facilities before pregnancy. Several epidemiological studies have reported that the seroprevalence varies widely from 4.6% to 74.6% among childbearing age women in some provinces of Iran (
3). However, there has been no study on the seroprevalence of infection in reproductive-age women in Birjand city. Therefore, this cross-sectional study aimed to determine the prevalence of anti-
T. gondii IgG antibodies and its associated risk factors among reproductive age women referring to Birjand Comprehensive Health Center, East of Iran.